Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2025-01-05T14:47:07.412Z Has data issue: false hasContentIssue false

2 - The Therapeutic Threshold and the Point of Futility

Published online by Cambridge University Press:  19 October 2021

Jonathan M. Meyer  and
Stephen M. Stahl
Jonathan M. Meyer
Affiliation:
University of California, San Diego
Stephen M. Stahl
Affiliation:
University of California, Riverside and San Diego
Get access

Summary

Prior to our modern understanding of differences in drug metabolism, it was apparent that a wide range of response to antipsychotic dosages existed, with some schizophrenia patients responding minimally regardless of dose. Whether this variation was due to nonadherence or other biological factors [1, 2], the need to quantify antipsychotic exposure and clinical response spurred interest in development of reliable laboratory assays and improved psychiatric research instruments in the 1960s. The Brief Psychiatric Rating Scale (BPRS) was developed in 1962 to rate major symptom characteristics of acute psychosis, and represented an important advancement over older methods that lacked “efficiency, speed and economy” [3].

Type
Chapter
Information
The Clinical Use of Antipsychotic Plasma Levels
Stahl's Handbooks
 , pp. 34 - 59
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Willcox, D. R., Gillan, R., and Hare, E. H. (1965). Do psychiatric out-patients take their drugs? BMJ, 2, 790–792.Google Scholar
Curry, S. H., Davis, J. M., Janowsky, D. S., et al. (1970). Factors affecting chlorpromazine plasma levels in psychiatric patients. Arch Gen Psychiatry, 22, 209–215.Google Scholar
Overall, J. E. and Gorham, D. R. (1962). The Brief Psychiatric Rating Scale. Psychological Reports, 10, 799–812.Google Scholar
Curry, S. H. (1968). The determination and possible significance of plasma levels of chlorpromazine in psychiatric patients. Agressologie, 9, 115–121.Google Scholar
Curry, S. H. and Marshall, J. H. (1968). Plasma levels of chlorpromazine and some of its relatively non-polar metabolites in psychiatric patients. Life Sci, 7, 9–17.Google Scholar
Kay, S. R., Fiszbein, A., and Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull, 13, 261–276.Google Scholar
Sakalis, G., Curry, S. H., Mould, G. P., et al. (1972). Physiologic and clinical effects of chlorpromazine and their relationship to plasma level. Clin Pharmacol Ther, 13, 931–946.Google Scholar
Van Putten, T., May, P. R., and Jenden, D. J. (1981). Does a plasma level of chlorpromazine help? Psychol Med, 11, 729–734.Google Scholar
Van Putten, T., Marder, S. R., Wirshing, W. C., et al. (1991). Neuroleptic plasma levels. Schizophr Bull, 17, 197–216.Google Scholar
Nielsen, J., Graff, C., Kanters, J. K., et al. (2011). Assessing QT prolongation of antipsychotic drugs. CNS Drugs, 25, 473–490.Google Scholar
Van Putten, T., Aravagiri, M., Marder, S. R., et al. (1991). Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients. Psychopharmacol Bull, 27, 91–96.Google Scholar
Meyer, J. M. (2014). A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes. CNS Spectr, 19, 432–438.Google Scholar
Hiemke, C., Bergemann, N., Clement, H. W., et al. (2018). Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry, 51, 9–62.Google Scholar
Barnes, T. R., Drake, R., Paton, C., et al. (2020). Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol, 34, 3–78.Google Scholar
Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020). Blood levels to optimize antipsychotic treatment in clinical practice; a joint consensus statement of the American Society of Clinical Psychopharmacology (ASCP) and the Therapeutic Drug Monitoring (TDM) Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). J Clin Psychiatry, 81, https://doi.org/10.4088/JCP.4019cs13169.Google Scholar
Midha, K. K., Hubbard, J. W., Marder, S. R., et al. (1994). Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. J Psychiatry Neurosci, 19, 254–264.Google Scholar
Marder, S. R., Davis, J. M., and Janicak, P. G., eds. (1993). Clinical Use of Neuroleptic Plasma Levels. Washington, DC: American Psychiatric Press Inc.Google Scholar
Meyer, J. M. (2020). Monitoring and improving antipsychotic adherence in outpatient forensic diversion programs. CNS Spectr, 25, 136–144.Google Scholar
Remington, G., Agid, O., Foussias, G., et al. (2013). Clozapine and therapeutic drug monitoring: Is there sufficient evidence for an upper threshold? Psychopharmacology (Berl), 225, 505–518.Google Scholar
Lopez, L. V. and Kane, J. M. (2013). Plasma levels of second-generation antipsychotics and clinical response in acute psychosis: A review of the literature. Schizophr Res, 147, 368–374.Google Scholar
Grandjean, E. M. and Aubry, J.-M. (2009). Lithium: Updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring. CNS Drugs, 23, 331–349.Google Scholar
Machado-Vieira, R., Otaduy, M. C., Zanetti, M. V., et al. (2016). A selective association between central and peripheral lithium levels in remitters in bipolar depression: A 3T-(7) Li magnetic resonance spectroscopy study. Acta Psychiatr Scand, 133, 214–220.Google Scholar
Uchida, H., Takeuchi, H., Graff-Guerrero, A., et al. (2011). Predicting dopamine D2 receptor occupancy from plasma levels of antipsychotic drugs: A systematic review and pooled analysis. J Clin Psychopharmacol, 31, 318–325.Google Scholar
Takeuchi, H., MacKenzie, N. E., Samaroo, D., et al. (2020). Antipsychotic dose in acute schizophrenia: A meta-analysis. Schizophr Bull, 46, 1439–1458.Google Scholar
Melkote, R., Singh, A., Vermeulen, A., et al. (2018). Relationship between antipsychotic blood levels and treatment failure during the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. Schizophr Res, 201, 324–328.Google Scholar
Correll, C. U., Jain, R., Meyer, J. M., et al. (2019). Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: Indirect comparison with other second-generation antipsychotics after treatment discontinuation. Neuropsychiatr Dis Treat, 15, 2537–2550.Google Scholar
Samara, M. T., Leucht, C., Leeflang, M. M., et al. (2015). Early improvement as a predictor of later response to antipsychotics in schizophrenia: A diagnostic test review. Am J Psychiatry, 172, 617–629.Google Scholar
Meyer, J. M. and Stahl, S. M. (2019). The Clozapine Handbook. Cambridge: Cambridge University Press.Google Scholar
Van Putten, T., Marder, S. R., and Mintz, J. (1985). Plasma haloperidol levels: Clinical response and fancy mathematics. Arch Gen Psychiatry, 42, 835–838.Google Scholar
Perry, P. J., Miller, D. D., Arndt, S. V., et al. (1991). Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry, 148, 231–235.Google Scholar
Kronig, M. H., Munne, R. A., Szymanski, S., et al. (1995). Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry, 152, 179–182.Google Scholar
Lu, M. L., Wu, Y. X., Chen, C. H., et al. (2016). Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor clinical efficacy in patients with schizophrenia. PLoS One, 11, e0148539.Google Scholar
Meyer, J. M. (2018). Pharmacotherapy of psychosis and mania. In Brunton, L. L., Hilal-Dandan, R., and Knollmann, B. C., eds., Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th edn. Chicago, IL: McGraw-Hill, pp. 279–302.Google Scholar
Farde, L., Hall, H., Ehrin, E., et al. (1986). Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science, 231, 258–261.Google Scholar
Kirino, S., Suzuki, T., Takeuchi, H., et al. (2017). Representativeness of clinical PET study participants with schizophrenia: A systematic review. J Psychiatr Res, 88, 72–79.Google Scholar
Arakawa, R., Takano, A., and Halldin, C. (2020). PET technology for drug development in psychiatry. Neuropsychopharmacol Rep, 40, 114–121.Google Scholar
de Haan, L., van Bruggen, M., Lavalaye, J., et al. (2003). Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry, 160, 303–309.Google Scholar
Kapur, S. and Seeman, P. (2001). Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry, 158, 360–369.Google Scholar
Perry, P. J., Lund, B. C., Sanger, T., et al. (2001). Olanzapine plasma concentrations and clinical response: Acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol, 21, 14–20.Google Scholar
Preskorn, S. H. (2010). Outliers on the dose–response curve: How to minimize this problem using therapeutic drug monitoring, an underutilized tool in psychiatry. J Psychiatr Pract, 16, 177–182.Google Scholar
Kapur, S., Zipursky, R., Jones, C., et al. (2000). Relationship between dopamine D(2) occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatry, 157, 514–520.Google Scholar
Marder, S. R. and Meibach, R. C. (1994). Risperidone in the treatment of schizophrenia. Am J Psychiatry, 151, 825–835.Google Scholar
Tadori, Y., Forbes, R. A., McQuade, R. D., et al. (2011). In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. Eur J Pharmacol, 668, 355–365.Google Scholar
Maeda, K., Sugino, H., Akazawa, H., et al. (2014). Brexpiprazole I: In vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther, 350, 589–604.Google Scholar
Mizrahi, R., Mamo, D., Rusjan, P., et al. (2009). The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. Int J Neuropsychopharmacol, 12, 715–721.Google Scholar
Sparshatt, A., Taylor, D., Patel, M. X., et al. (2010). A systematic review of aripiprazole – dose, plasma concentration, receptor occupancy, and response: Implications for therapeutic drug monitoring. J Clin Psychiatry, 71, 1447–1556.Google Scholar
Girgis, R. R., Slifstein, M., D’Souza, D., et al. (2016). Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. Psychopharmacology (Berl), 233, 3503–3512.Google Scholar
Girgis, R. R., Forbes, A., Abi-Dargham, A., et al. (2020). A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia. Neuropsychopharmacology, 45, 786–792.Google Scholar
Mamo, D., Graff, A., Mizrahi, R., et al. (2007). Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: A triple tracer PET study. Am J Psychiatry, 164, 1411–1417.Google Scholar
Wiesel, F. A., Farde, L., Nordstrom, A. L., et al. (1990). Central D1- and D2-receptor occupancy during antipsychotic drug treatment. Prog Neuro-Psychopharmacol Biol Psychiatry, 14, 759–767.Google Scholar
Gefvert, O., Bergstrom, M., Langstrom, B., et al. (1998). Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology, 135, 119–126.Google Scholar
Vanover, K. E., Davis, R. E., Zhou, Y., et al. (2019). Dopamine D2 receptor occupancy of lumateperone (ITI-007): A Positron Emission Tomography Study in patients with schizophrenia. Neuropsychopharmacology, 44, 598–605.Google Scholar
Meltzer, H. Y. and Roth, B. L. (2013). Lorcaserin and pimavanserin: Emerging selectivity of serotonin receptor subtype-targeted drugs. J Clin Invest, 123, 4986–4991.Google Scholar
Stahl, S. M. (2016). Mechanism of action of pimavanserin in Parkinson’s disease psychosis: Targeting serotonin 5HT2A and 5HT2C receptors. CNS Spectr, 21, 271–275.Google Scholar
Shekhar, A., Potter, W. Z., Lightfoot, J., et al. (2008). Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry, 165, 1033–1039.Google Scholar
Barak, S. and Weiner, I. (2011). The M1/M4 preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: Putative efficacy against positive, negative and cognitive symptoms in schizophrenia. Int J Neuropsychopharmacol, 14, 1233–1246.Google Scholar
Simmler, L. D., Buchy, D., Chaboz, S., et al. (2016). In vitro characterization of psychoactive substances at rat, mouse, and human trace amine-associated receptor 1. J Pharmacol Exp Ther, 357, 134–144.Google Scholar
Dedic, N., Jones, P. G., Hopkins, S. C., et al. (2019). SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action. J Pharmacol Exp Ther, 371, 1–14.Google Scholar
Cohen, W. J. and Cohen, N. H. (1974). Lithium carbonate, haloperidol, and irreversible brain damage. JAMA, 230, 1283–1287.Google Scholar
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 353, 1209–1223.Google Scholar
Leucht, S., Samara, M., Heres, S., et al. (2014). Dose equivalents for second-generation antipsychotics: The minimum effective dose method. Schizophr Bull, 40, 314–326.Google Scholar
Leucht, S., Samara, M., Heres, S., et al. (2016). Dose equivalents for antipsychotic drugs: The DDD method. Schizophr Bull, 42 Suppl 1, S90–94.Google Scholar
Rothe, P. H., Heres, S., and Leucht, S. (2018). Dose equivalents for second generation long-acting injectable antipsychotics: The minimum effective dose method. Schizophr Res, 193, 23–28.Google Scholar
Gardner, D. M., Murphy, A. L., O’Donnell, H., et al. (2010). International consensus study of antipsychotic dosing. Am J Psychiatry, 167, 686–693.Google Scholar
Leucht, S., Crippa, A., Siafis, S., et al. (2020). Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia. Am J Psychiatry, 177, 342–353.Google Scholar
Kapur, S., Remington, G., Zipursky, R. B., et al. (1995). The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A PET study. Life Sci, 57, PL103–107.Google Scholar
Nord, M. and Farde, L. (2011). Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther, 17, 97–103.Google Scholar
de Haan, L., Lavalaye, J., Linszen, D., et al. (2000). Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry, 157, 1019–1020.Google Scholar
Lataster, J., van Os, J., de Haan, L., et al. (2011). Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: An experience sampling study. J Clin Psychiatry, 72, 1397–1404.Google Scholar
Veselinovicć, T., Scharpenberg, M., Heinze, M., et al. (2019). Dopamine D2 receptor occupancy estimated from plasma concentrations of four different antipsychotics and the subjective experience of physical and mental well-being in schizophrenia: Results from the randomized NeSSy Trial. J Clin Psychopharmacol, 39, 550–560.Google Scholar
Remington, G., Mamo, D., Labelle, A., et al. (2006). A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry, 163, 396–401.Google Scholar
Simpson, G. M. and Kunz-Bartholini, E. (1968). Relationship of individual tolerance, behavior and phenothiazine produced extrapyramidal system disturbance. Dis Nerv System, 29, 269–274.Google Scholar
Miller, R. S., Peterson, G. M., McLean, S., et al. (1995). Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate. J Clin Pharm Ther, 20, 55–62.Google Scholar
Nyberg, S., Dencker, S. J., Malm, U., et al. (1998). D(2)- and 5-HT(2) receptor occupancy in high-dose neuroleptic-treated patients. Int J Neuropsychopharmacol, 1, 95–101.Google Scholar
Cohen, D. (2014). Prescribers fear as a major side-effect of clozapine. Acta Psychiatr Scand, 130, 154–155.Google Scholar
Gee, S., Vergunst, F., Howes, O., et al. (2014). Practitioner attitudes to clozapine initiation. Acta Psychiatr Scand, 130, 16–24.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×